Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a single surgery technique improve life after stomach cancer in two countries?

NCT ID NCT07800819

Knowledge-focused Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

This study looks back at medical records from high-volume hospitals in Russia and China to compare how patients with stomach cancer or cancer at the junction of the stomach and esophagus fare after a specific surgery called proximal gastrectomy with double-tract reconstruction. Researchers will examine postoperative acid reflux, nutritional status, complications, and long-term survival. By matching similar patients from both countries, they aim to see whether outcomes differ and what factors influence recovery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Proximal gastrectomy with double-tract reconstruction (a surgical procedure)
What this could lead to
If successful, this analysis could clarify which patients benefit most from this surgery and guide surgeons in choosing the best reconstruction method to reduce reflux and improve nutrition.
What could go wrong
This is a retrospective review of existing records, not a controlled experiment, so differences between patient groups may bias the results. Findings may not apply to other hospitals or populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients treated from June 2015 through June 2025 at either participating center who underwent curative proximal gastrectomy with double-tract reconstruction for proximal gastric adenocarcinoma or Siewert type II/III adenocarcinoma of the esophagogastric junction.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18 to 75 years. 2. Histologically confirmed gastric adenocarcinoma or Siewert type II/III adenocarcinoma of the esophagogastric junction. 3. Underwent proximal gastrectomy with double-tract reconstruction. 4. Surgery performed with curative intent. 5. At least one valid postoperative follow-up record containing reflux, nutritional, or complication information. 6. Clinical, pathological, operative, and follow-up data sufficiently complete for analysis, with less than 20 percent missingness in key variables. Exclusion Criteria: 1. Previous gastric or esophageal surgery, except limited endoscopic treatment such as endoscopic mucosal resection. 2. Synchronous or metachronous malignancy, except cured non-melanoma skin cancer or cervical carcinoma in situ. 3. Complete absence of follow-up data. 4. Double-tract reconstruction not completed or changed to another reconstruction method. 5. Severe preoperative reflux disease, defined as GERD-Q score greater than 8 with a requirement for long-term medication.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adenocarcinoma of the esophagogastric junction are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal junction adenocarcinoma peptic esophagitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adenocarcinoma of the esophagogastric junction Gastric adenocarcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • First Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, China

  • Moscow Clinical Scientific Center named after A.S. Loginov

    Moscow, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.